This HTML5 document contains 127 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00991/identifier/national-drug-code-directory/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00991/identifier/chemspider/
n23http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00991/identifier/wikipedia/
n21http://www.rxlist.com/cgi/generic/
n28http://linked.opendata.cz/resource/drugbank/patent/
n30http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00991/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n27http://linked.opendata.cz/resource/drugbank/medicinal-product/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00991/identifier/kegg-compound/
owlhttp://www.w3.org/2002/07/owl#
n25http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n31http://www.drugs.com/cdi/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00991/identifier/bindingdb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00991/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00991/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00991/identifier/kegg-drug/
n18http://linked.opendata.cz/ontology/sukl/drug/
n29http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00991/identifier/drugbank/

Statements

Subject Item
n2:DB00991
rdf:type
n3:Drug
n3:description
Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
n3:dosage
n17:271B4AFF-363D-11E5-9242-09173F13E4C5 n17:271B4B00-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Heller B, Tarricone R: Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Curr Med Res Opin. 2004 Aug;20(8):1279-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15324531
n3:group
approved
n3:halfLife
54.9 hours
n3:indication
Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.
n3:manufacturer
n5:271B4AF3-363D-11E5-9242-09173F13E4C5 n5:271B4AF4-363D-11E5-9242-09173F13E4C5 n5:271B4AF1-363D-11E5-9242-09173F13E4C5 n5:271B4AF2-363D-11E5-9242-09173F13E4C5 n5:271B4AF7-363D-11E5-9242-09173F13E4C5 n5:271B4AF5-363D-11E5-9242-09173F13E4C5 n5:271B4AF6-363D-11E5-9242-09173F13E4C5 n5:271B4AF8-363D-11E5-9242-09173F13E4C5 n5:271B4AFB-363D-11E5-9242-09173F13E4C5 n5:271B4AF9-363D-11E5-9242-09173F13E4C5 n5:271B4AFA-363D-11E5-9242-09173F13E4C5
owl:sameAs
n23:DB00991 n30:DB00991
dcterms:title
Oxaprozin
adms:identifier
n7:4453 n8:DB00991 n9:50002861 n10:D00463 n11:0025-1381-31 n12:C07356 n13:46506429 n14:PA450730 n15:4614 n24:Oxaprozin
n3:mechanismOfAction
Anti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective NSAID, with a cell assay system showing lower COX-2 selectivity implying higher COX-1 selectivity.
n3:packager
n5:271B4AEA-363D-11E5-9242-09173F13E4C5 n5:271B4AF0-363D-11E5-9242-09173F13E4C5 n5:271B4AE6-363D-11E5-9242-09173F13E4C5 n5:271B4AE7-363D-11E5-9242-09173F13E4C5 n5:271B4AE4-363D-11E5-9242-09173F13E4C5 n5:271B4AE5-363D-11E5-9242-09173F13E4C5 n5:271B4AE2-363D-11E5-9242-09173F13E4C5 n5:271B4AE3-363D-11E5-9242-09173F13E4C5 n5:271B4AE0-363D-11E5-9242-09173F13E4C5 n5:271B4AE1-363D-11E5-9242-09173F13E4C5 n5:271B4ADE-363D-11E5-9242-09173F13E4C5 n5:271B4ADF-363D-11E5-9242-09173F13E4C5 n5:271B4ADC-363D-11E5-9242-09173F13E4C5 n5:271B4ADD-363D-11E5-9242-09173F13E4C5 n5:271B4ADA-363D-11E5-9242-09173F13E4C5 n5:271B4ADB-363D-11E5-9242-09173F13E4C5 n5:271B4AD8-363D-11E5-9242-09173F13E4C5 n5:271B4AD9-363D-11E5-9242-09173F13E4C5 n5:271B4AD6-363D-11E5-9242-09173F13E4C5 n5:271B4AD7-363D-11E5-9242-09173F13E4C5 n5:271B4AD4-363D-11E5-9242-09173F13E4C5 n5:271B4AD5-363D-11E5-9242-09173F13E4C5 n5:271B4AD2-363D-11E5-9242-09173F13E4C5 n5:271B4AD3-363D-11E5-9242-09173F13E4C5 n5:271B4AD0-363D-11E5-9242-09173F13E4C5 n5:271B4AD1-363D-11E5-9242-09173F13E4C5 n5:271B4ACE-363D-11E5-9242-09173F13E4C5 n5:271B4ACF-363D-11E5-9242-09173F13E4C5 n5:271B4ACD-363D-11E5-9242-09173F13E4C5 n5:271B4AEF-363D-11E5-9242-09173F13E4C5 n5:271B4AED-363D-11E5-9242-09173F13E4C5 n5:271B4AEE-363D-11E5-9242-09173F13E4C5 n5:271B4AEB-363D-11E5-9242-09173F13E4C5 n5:271B4AEC-363D-11E5-9242-09173F13E4C5 n5:271B4AE8-363D-11E5-9242-09173F13E4C5 n5:271B4AE9-363D-11E5-9242-09173F13E4C5
n3:patent
n28:6030643
n3:routeOfElimination
Oxaprozin is expected to be excreted in human milk based on its physical-chemical properties; however, the amount of oxaprozin excreted in breast milk has not been evaluated. Approximately 95% of oxaprozin is metabolized by the liver. Approximately 5% of the oxaprozin dose is excreted unchanged in the urine. Sixty-five percent (65%) of the dose is excreted in the urine and 35% in the feces as metabolite. Biliary excretion of unchanged oxaprozin is a minor pathway. Several oxaprozin metabolites have been identified in human urine or feces.
n3:synonym
Daypro Duraprox Oxaprozina Walix Oxaprozinum Oxaprozine Deflam Danoprox Dayrun
n3:toxicity
Oral, mouse: LD<sub>50</sub> = 1210 mg/kg; Oral, rabbit: LD<sub>50</sub> = 172 mg/kg; Oral, rat: LD<sub>50</sub> = 4470 mg/kg
n3:volumeOfDistribution
* 11 to 17 L/70 kg
n18:hasAHFSCode
n19:28-08-04-92
n3:foodInteraction
Take with food, usually once a day after breakfast. Food decreases the rate of absorption but not the amount absorbed. Avoid alcohol.
n3:proteinBinding
>99.5% bound to albumin
n3:synthesisReference
# Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19952416
n25:hasConcept
n26:M0052829
foaf:page
n21:oxaproz.htm n31:oxaprozin.html
n3:IUPAC-Name
n4:271B4B05-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4B0B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4B0A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4B07-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4B08-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4B09-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4B03-363D-11E5-9242-09173F13E4C5 n4:271B4B1B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4B04-363D-11E5-9242-09173F13E4C5 n4:271B4B01-363D-11E5-9242-09173F13E4C5 n4:271B4B1D-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4B02-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4B1E-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n29:M01AE12
n3:H-Bond-Acceptor-Count
n4:271B4B11-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4B12-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4B0C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4B0D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4B0F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4B0E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4B10-363D-11E5-9242-09173F13E4C5
n3:absorption
Oxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
21256-18-8
n3:category
n3:containedIn
n27:271B4AFE-363D-11E5-9242-09173F13E4C5 n27:271B4AFC-363D-11E5-9242-09173F13E4C5 n27:271B4AFD-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4B17-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4B19-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4B1A-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4B1C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4B16-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4B15-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4B18-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4B06-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4B13-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4B14-363D-11E5-9242-09173F13E4C5